Notably, these pathways were significantly co‐activated with chemoresistance at the same time, suggesting that LOX may promote treatment resistance through a dual mechanism: first, by enhancing tumour cell plasticity through EMT, and second, by maintaining survival signalling through PI3K/AKT/mTOR pathway. The gene discussed is MTOR; the disease is neoplasm.